Skip to main content

$0.040 0.004 (11.11%)

High

$0.04

Low

$0.04

Trades

37

Turnover

$81,892

Volume

2,106,389
30 June 2023 at 3:45pm
Register to track NTI and receive email alerts.

Commencement of Phase II/III ASD Clinical Trial

StockBot

416,823 posts

NTI released this announcement to the ASX on 19 December 2022, 13:04. The announcement is marked as price sensitive, and is 2 page(s) in length and 179.16kb in size.

You can view all announcements from NTI and see how they appear on a price chart on the announcements page.

At the date of this announcement, NTI was 0.098% short sold according to ASIC data. It was ranked the 480th most shorted stock on the ASX. It remains ranked 538th as of the latest reported data (23 January 2026).

Other Recent Announcements from NTI
Notification of cessation of securities - NTI 30 June 2023, 17:06
Notification regarding unquoted securities - NTI 28 June 2023, 16:14
NTI to Present at Rett Syndrome Foundation Meeting 5 June 2023, 8:27
Commencement of Phase II/III ASD Clinical Trial 19 December 2022, 13:04
Results of Meeting 30 November 2022, 19:53
2022 Annual General Meeting Presentation 30 November 2022, 18:09
Chairman Address to 2022 Annual General Meeting 30 November 2022, 18:01
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track NTI and receive email alerts.